ARGENX SE (ARGX) Stock
ARGX has an Alpha Score of 66 out of 100 (moderate), computed on Nov 6, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 2 trades in ARGX since 2023: 1 purchase and 1 sale, most recently Alan Armstrong (purchase, Mar 30, 2026). 5 of the hedge funds AlphaScala tracks reported ARGX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $197.07M. Its trailing P/E ratio is 20.9 and its net margin 30.4% (key statistics as of Nov 4, 2026).
What is ARGX's Alpha Score?
How it works →Alpha Score of 66 reflects moderate overall profile with strong momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded ARGENX SE (ARGX)?
Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Jul 10, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-07-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all ARGX political trades →Which hedge funds own ARGX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 212K | $197.07M | -3% |
| Millennium Management Israel Englander | 94K | $87.58M | +30% |
| Point72 Steve Cohen | 40K | $37.10M | NEW |
| D.E. Shaw David Shaw | 8K | $7.67M | -84% |
| Bridgewater Associates Ray Dalio | 2K | $1.82M | +61% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are ARGX's key statistics?
Key statistics as of Nov 4, 2026
How does ARGX's valuation compare with the Healthcare sector?
| Metric | ARGX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 20.9 | 28.8 | 111 |
| Net margin | 30.36% | 4.31% | 164 |
| Return on equity | 22.43% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
ARGX price chart
Powered by TradingViewWhat does ARGENX SE do?
argenx SE is a global, commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in antibody-based therapies for severe autoimmune diseases. The company developed and commercializes VYVGART (efgartigimod), the first approved neonatal Fc receptor (FcRn) blocker, which is now available in more than 30 countries for treating conditions including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. argenx leverages its proprietary antibody engineering technologies—including NHANCE, ABDEG, and POTELLIGENT platforms—combined with its Immunology Innovation Program to develop a diverse pipeline of novel medicines. Beyond its lead FcRn program, the company is advancing empasiprubart, a C2 complement inhibitor in Phase 3 development, alongside several earlier-stage experimental candidates targeting various autoimmune indications across neurology, rheumatology, and hematology. Through strategic partnerships with academic researchers and pharmaceutical collaborators, argenx translates immunology breakthroughs into clinical therapies, focusing on rare and serious autoimmune conditions with significant unmet medical needs.